Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Expanding evidence leads to new pharmacogenomics payer coverage

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Relling, M. V., Klein, T. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M. & Caudle, K. E. The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clin. Pharmacol. Ther. 107, 171–175 (2020).

    Article  Google Scholar 

  2. 2.

    Berm, E. J. et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One 11, e0146262 (2016).

    Article  Google Scholar 

  3. 3.

    Kogan, J. N., Empey, P., Kanter, J., Keyser, D. J. & Shrank, W. H. Delivering on the value proposition of precision medicine: the view from healthcare payers. Am. J. Manag. Care 24, 177–179 (2018).

    PubMed  Google Scholar 

  4. 4.

    Hefti, E. & Blanco, J. G. Documenting pharmacogenomic testing with CPT codes. J. AHIMA 87, 56–59 (2016).

    PubMed  PubMed Central  Google Scholar 

  5. 5.

    Palmetto, G. B. A. Local Coverage Determination (LCD): MolDX: Pharmacogenomics Testing (L38294). (2020).

  6. 6.

    Caudle, K. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M., Relling, M. V. & Klein, T. E. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am. J. Health Syst. Pharm. 73, 1977–1985 (2016).

    CAS  Article  Google Scholar 

  7. 7.

    Anderson, H. D., Crooks, K. R., Kao, D. P. & Aquilante, C. L. The landscape of pharmacogenetic testing in a US managed care population. Genet. Med. 22, 1247–1253 (2020).

    CAS  Article  Google Scholar 

  8. 8.

    Centers for Medicare & Medicaid Services. Who are the MACs. (2020).

  9. 9.

    US Food and Drug Administration. The FDA warns against the use of many genetic tests with unapproved claims to predict patient response to specific medications: FDA safety communication. (2018).

  10. 10.

    US Food and Drug Administration. Table of pharmacogenetic associations. (2018).

  11. 11.

    US Department of Health and Human Services. Rescission of guidances and other informal issuances concerning premarket review of laboratory developed tests. (2020).

Download references

Author information



Corresponding author

Correspondence to Philip E. Empey.

Ethics declarations

Competing interests

P.E.E. is a Co-Investigator on Implementing Genomics in Practice (IGNITE) project grant (U01 HG010245) and has provided consultative services for Cipherome. V.M.P. reports the following: the Indiana University School of Medicine Pharmacogenomics Laboratory is a fee-for-service clinical laboratory that offers clinical pharmacogenetic testing. V.M.P. is supported by the IGNITE project grants (U01 HG007762 and HG010245) and is on the clinical advisory board of Avalon Healthcare Solutions. J.M.H. is a Co-Investigator for CPIC (NIH/NHGRI U24HG010135). K.E.C. is the Co-Principal Investigator for CPIC (NIH/NHGRI U24HG010135). T.E.K. is the Co-Principal Investigator for the PharmGKB (NIH/NHGRI/NICHD U24 HG010615), CPIC (NIH/NHGRI U24HG010135) and PharmCAT (NIH/NHGRI U24 HG010862). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Empey, P.E., Pratt, V.M., Hoffman, J.M. et al. Expanding evidence leads to new pharmacogenomics payer coverage. Genet Med 23, 830–832 (2021).

Download citation


Quick links